• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MediciNova, Inc. - Common Stock (NQ:MNOV)

    1.450 +0.050 (+3.58%)
    Streaming Delayed Price Updated: 1:18 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about MediciNova, Inc. - Common Stock

    < Previous 1 2 3 Next >
    MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
    Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients 
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova to Present at the LD Micro Main Event XIX Investor Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
    ~Patient Recruitment Closed~ 
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Provides Shareholder Update on Key Developments
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
    MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients 
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
    From MediciNova, Inc.
    Via GlobeNewswire
    First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
    NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy 
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
    Academic group to receive a total of $22 million for the trial 
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
    From MediciNova, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.